Canada’s Marihuana for Medical Purposes Regulations (“MMPR”) have generated a lot of attention within the investment community. After Tweed Marijuana Inc.’s (OTC: TWMJF) (TSX-V: TWD) debut, investment dollars began to flow into the sector through both approved and upcoming opportunities in the space. Investors have many different options in the space, which can make it confusing to navigate.

Supreme Pharmaceuticals Inc. (OTC: SPRWF) (CSE: SL) is a promising opportunity in the space. After purchasing a 342,000 square foot facility back in May of 2014, the company has spent approximately $4 million in capital to transform the former tomato greenhouse into a state-of-the-art hybrid marijuana growing facility complete with R&D space, security installations, and advanced automation and growing controls.

CannabisFN recently interviewed John Fowler, the President, at Supreme Pharmaceuticals while he was onsite at the hybrid greenhouse facility. In this brief interview Mr. Fowler discusses the company’s progress thus far and its significant plans for growth in 2015.

Short-term Outlook

Supreme Pharmaceuticals is currently in the latter stages of the Canadian licensing process in regards to its proposal to produce and sell up to 24,000 kg of medical marijuana annually from its 7 acre hybrid greenhouse facility in Kincardine, Ontario. To date, the company has completed $4 million worth of facility upgrades and is awaiting pre-license inspection from Health Canada.

The company has been supported through this process by strong support form the local community including municipal administrators, contractors and local residents. Management credits this support as a large factor in its ability to succeed in completing the pre-license construction as quickly and effectively as it has done.

If successful in obtaining licensed producer status, the company expects to immediately commence growing in its first completed phase of the facility. The next phases of development will be built out in 2015 in order to further increase the facility’s capacity, while maintaining pace with increasing demand for the medicine.

If the company begins growing operations over the next few weeks, shareholders could start to see meaningful revenue and profit in 2015. The company’s high caliber quality control and growing teams will help the production schedule stay on track, while also ensuring that the end product is both high quality and affordable for medical marijuana patients in need throughout Canada.

Long-term Goals

Supreme Pharmaceuticals’ long-term goals provide additional reasons for cannabis investors to consider the stock. When the management team set out to grow medical marijuana, they decided that it was necessary to produce high quality marijuana that could be made available at an affordable price. These necessities prompted a unique business model that has significant long-term potential in the market.

Many marijuana-growing operations use indoor techniques and technologies pioneered by companies like Fusion Pharm Inc. (OTC: FSPM) and GreenGro Technologies Inc. (OTC: GRNH). The problem with these approaches is that electricity costs can quickly add up, while many lighting solutions only provide a certain spectrum of light, which can have an effect on the plant’s biology.


Supreme Pharmaceuticals’ hybrid greenhouse combines free, natural, and full-spectrum sunlight with proprietary design, automation, and environmental controls that provide the quality and standardization that indoor growing permits. As a result, the company is able to keep its electricity costs down, ensure a high quality plant, and deliver the best of both worlds for its patients and shareholders.

Compelling Opportunity

Supreme Pharmaceuticals trades with a market capitalization of approximately C$24 million, compared to Tweed’s C$89 million market capitalization or Bedrocan Cannabis Corp.’s (OTC: BNRDF) (TSX-V: BED) C$54 million market capitalization. If approved as a licensed producer, the company could see its market capitalization appreciate to these levels over time.

In the meantime, the company’s many near-term catalysts – in the form of Health Canada’s pending inspection and ultimately its production – could pave the way for price appreciation over the coming months, if it’s successful. Cannabis investors may want to keep a close eye on the stock over the coming months, as the company works toward becoming a fully approved licensed producer of medical marijuana.

For more information, visit the company’s website at or CannabisFN’s profile at

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: